Background Triple-negative breast cancer (TNBC) occurs at higher frequency in African Americans compared with Caucasians. It is unclear if the biology of TNBC is different in African American versus Caucasians. In this study, we sought to evaluate racial differences in the molecular pathology of TNBC. Methods Using data from The Cancer Genome Atlas, we identified TNBC patients with information on race. We analyzed differences in clinical characteristics, tumor somatic mutations, and gene expression patterns by race from whole exome and microarray data. Results 1104 patients were identified, of which 178 had TNBC. TNBC was more frequent in African Americans than Caucasians (33.3 vs 14.9%). Although more African Americans than Caucasians overall were classified as basal-like from PAM50 gene expression (34.8 vs 16.1%), no differences in the TNBC cohort were observed. Median tumor somatic mutation counts were higher in African Americans versus Caucasians (39.5 vs 34), but no racial differences in the mutation counts in TNBC were observed. Somatic mutation analysis revealed racial differences in specific high prevalence genes in all patients (TP53 46% in African Americans vs 27% in Caucasians; PIK3CA 23% in African Americans vs 34% in Caucasians; and MLL3 12% in African Americans vs 6% in Caucasians). TNBC patients did not have any specific high prevalence genes associated with racial differences. There were no racial differences in gene expression patterns in selected genes involved in breast cancer biology. Overall, African Americans had shorter TTP and worse DFS. Racial differences in clinical outcomes were not observed in TNBC. Conclusion The mutational landscape of TNBC is similar between African Americans and Caucasians. The higher frequency of TNBC in African Americans is therefore not associated with a different genomic profile of commonly established tumor regulatory pathway genes. Other modifiable factors may exist that contribute to the racial disparity in TNBC.
Introduction
Although breast cancer mortality rates have been dropping since 1990 due to earlier detection and improved treatment modalities, substantial racial disparities in outcome persist. Breast cancer occurs at a lower frequency in black women, but is associated with a poorer overall and breast cancer specific survival [1, 2] . Outcome disparities persist even after controlling for socioeconomic factors such as access to care [3, 4] . Blacks with breast cancer are also more likely to present at earlier ages than whites, and to have tumors with more aggressive characteristics, such as high histologic grade and triple-negative breast cancers (TNBC) [5, 6] . In the Carolina Breast Cancer Study, the prevalence of TNBC was highest (39%) among black premenopausal women compared to other groups of patients (14-16%) [7] . It could be suggested that the preponderance of TNBC among black women could be due to their younger age at diagnosis, but even in older age groups, blacks are more likely than whites to present with TNBC [8] . This subtype has a less favorable prognosis than the others, particularly Luminal A subtype, which has the highest survival rates [7] .
It is possible that racial disparities in outcome are being driven by those with hormone receptor (HR)-positive cancers versus TNBC. Black women with HR-positive breast cancer have a much higher mortality rate in the first 2 years after diagnosis than whites [2] , but among those with TNBC, there is conflicting data on survival outcomes according to race [2, [9] [10] [11] [12] [13] [14] [15] . Although studies in breast cancer patients in general have identified racial differences in genomic profiles [16, 17] , it is unclear if these differences are being driven by those with HR-positive cancers or TNBC. To address this lack of data, we sought to investigate racial differences in the genetic landscape of TNBC.
Methods

Patient population
From the publicly available Cancer Genome Atlas (TCGA) database, we identified 1104 patients with primary breast cancer, who had undergone whole exome next generation sequencing with a somatic mutation report. Patients were diagnosed between 1988 and 2013, and clinical information was submitted to the TCGA between March 2010 and January 2015. Patients without information on race were excluded.
Statistical analysis
Chi squared or fisher's exact test and analysis of variance were used, to compare baseline categorical and continuous variables across race groups. Tumor-specific somatic mutations from whole exome next generation sequencing were analyzed. Sequencing was done at minimum coverage of 70% and at a depth of 209 as previously described [18] . We included genes with a prevalence of at least 5% in the TCGA breast cancer database. Gene expressions were assessed with TCGA microarray data. Two sample t tests were used to identify differentially expressed genes (DEGs) between African Americans and Caucasians. P values per gene level from hypothesis testing were adjusted to address multiple testing issues by the false discovery rate adjustment method. Differences in gene expression between race groups were calculated to sort gene list and then top DEGs as well as other genes relevant in breast cancer biology were selected. Java Treeview was used to generate a heat map to graphically represent gene expression values by race. To determine whether race was differentially associated with disease-free survival (DFS), the Cox proportional hazards model was applied and nonbreast cancer deaths were treated as competing risk events. Kaplan-Meier method and log-rank test were used to show differences in DFS by race. All statistical analyses were performed by SAS (version 9.4, SAS Institute, Cary, NC). Statistical significance was assessed as two-sided p \ 0.05. (Fig. 1a) . In the TNBC cohort, there were no racial differences in PAM50 categorization (91 vs 80.6%; p = .842) (Fig. 1b) .
Results
The median somatic mutation number per tumor was higher in all African American versus Caucasian patients with breast cancer overall (39.5 vs 34; p = .022). Although there were more somatic mutation numbers per tumor in the cohort of TNBC patients compared with all breast cancers (Fig. 2) , there were no racial differences in the TNBC cohort (56 vs 60; p = .399). Figure 3 shows the distribution of mutation numbers per tumor in all patients and in TNBC patients according to race. Somatic mutation analysis revealed racial differences in high prevalence ([5% in the TCGA dataset) genes (TP53, PIK3CA, MLL3) in all breast cancer patients, irrespective of clinical subtype (Table 2) . TP53 alterations were observed in 46% of all African Americans versus 27% of all Caucasians; p value \ 0.001, PIK3CA alterations: 23% in all African Americans versus 34% in all Caucasians; p value 0.021, and MLL3 alterations: 12% in all African Americans versus 6% in all Caucasians; p value 0.034. The TNBC patients did not have any high prevalence genes associated with racial differences between African Americans and Caucasians. Table 2 also shows the differences in high prevalence genes between the TNBC versus non-TNBC patients (CDH1, GATA3, MAP3K1, PIK3CA, TP53, TTN).
Microarray data were analyzed in order to delineate racial differences in gene expression patterns. The top 20 up-or down-regulated genes with the highest standardized mean racial differences in expression are listed in Table 3 . Other important genes in selected pathways in breast cancer biology were also evaluated. Genes selected included basal markers (KRT5, KRT14, KRT 17), luminal (KRT18, KRT19, ERS1, PgR, GATA3, ERBB2), epithelial to mesenchymal transition-EMT (VIM, SNAI1, SNAI2, TWIST1, TWST2, ZEB1, ZEB2, CDH1, CLDN3, CLDN4, CLDN7), stem cell/epithelial differentiation (CD44, CD24, EPCAM, MME, ITGA6, ITGB1, MUC1, THY1, ALDH1A1, WNT4, WNT16, SOX4), and cell migration/adhesion/metastasis (CDH2, KRAS, CDC42, RAC1, ICAM1, SRGAP2). We also included our previously described somatically mutated high prevalence genes with racial differences in all patients (TP53, PIK3CA, MLL3, FBXW7, KIAA2018, KIF4A, LOXHD1, MLLT10, ACVR2A, FAT1, IQSEC1, LARP4B, NRXN1). The cluster heat map for TNBC patients showed no apparent clustering by race (Fig. 4) . Evaluated of expression differences in other specific genes with potential therapeutic implications in TNBC (AR, PTEN, RB) also did not reveal racial differences-data not shown.
At 6 years of follow-up, African Americans with breast cancer had a shorter time to progression (TTP) (hazard ratio 1.5, p value 0.012) as well as worse DFS than Caucasians (Fig. 5 ). African Americans with basal-like tumors by PAM50 subtyping had the worst DFS outcomes (Fig. 6) . No racial differences in TTP or DFS were observed in the TNBC patients.
Discussion
Our study is one of the few to systematically examine racial differences in molecular characteristics specifically in patients with TNBC. We evaluated racial differences in clinical characteristics and outcome, somatic mutations both quantitatively and qualitatively, as well as gene Our results are consistent with and build upon another large population-based study showing differences in somatic mutations in TP53, PIK3CA by race, more basallike tumors by PAM50 classification in African Americans, and greater intratumor genetic heterogeneity in African Americans and those with HR-positive disease [19] . This study also showed no racial differences in somatic mutation frequency in the TNBC cohort.
These findings have two implications. First, racial disparities in breast cancer are likely being driven by differences in those with HR-positive disease. Although previous studies have shown inconsistent results regarding racial differences in outcome in patients with TNBC [5, 10, 14, [20] [21] [22] , we have previously shown that survival outcomes between African Americans and Caucasians with TNBC are similar [12] . Other large studies have shown that in those with HR-positive breast cancer, survival outcomes among African Americans are significantly worse than Caucasians [21] [22] [23] . An analysis comparing the outcomes of African American with non-African Americans breast cancer patients treated on a large randomized phase III adjuvant trial reported inferior disease-free and overall survival outcomes for HR-positive African Americans patients [22] . TNBC patients did not have any differences in outcome by race. Possible explanations for this phenomenon include variations in treatment due to access or compliance, comorbidities, reduced ER expression in African Americans, or higher frequency of obesity in African Americans and consequently higher levels of endogenous estrogens. It is important to note that HRpositive breast cancer is also genomically diverse [24] , and it could be postulated that racial differences in this subtype may be due to underlying genomic or epigenetic instability [25] , or differences in genes involved in DNA repair [26] or hormone metabolism [27] .
Secondly, the higher frequency of TNBC in African Americans is unlikely due to differences in molecular underpinnings, but other modifiable factors. In the Carolina Breast Cancer Study (CBCS), Millikan et al. showed that TNBC was associated with different risk factors related to obesity and reproductive history compared with HR-positive breast cancer. Patients with TNBC were more likely to have an advanced age at first full-term pregnancy (AFFTP), higher parity combined with reduced breastfeeding duration or number of children breastfed, and early-onset weight gain [28] . The authors also make reference to a proposed theory concerning the prognosis of breast cancer being predetermined by the spectrum of mutations the precursor cells obtain early in the carcinogenesis process [29] , suggesting that perhaps poor prognostic cancers, such as TNBC, have a different etiology than more favorable cancers. It is therefore feasible to speculate that African Americans exposed to certain endocrine or metabolic risk factors earlier on may be predisposed to aggressive breast cancers via early insults to precursor cells. Recent data from the Nurses' Health Study II also showed that physical activity between menarche and AFFTP reduces the risk of breast cancer in women with a long interval between these two events [30] , also suggesting that early life exposures affect breast cancer risk. Public health interventions such as reducing obesity and promoting breastfeeding may have an impact in reducing the incidence of TNBC in African Americans.
The data from the current study must be interpreted in light of its limitations. We are not able to report the impact of sociodemographic variables on outcome in this study. While it is feasible that the worse outcome observed in African Americans with breast cancer may be due to sociodemographic factors, we would have expected to see a similar finding in the TNBC cohort if these factors explained majority of the disparities. The absence of systemic therapy information did not allow us to control for the impact of chemotherapy on clinical outcome, or even explore the association of neoadjuvant chemotherapy with mutation burden in those with residual disease. As African Americans tend to be more obese than Caucasians [31, 32] , it is possible they have worse outcomes due to reduced systemic exposure to chemotherapy from dose capping in patients with higher body surface areas [33] [34] [35] . However, poorer survival in African Americans should also have been apparent in the TNBC cohort if this was a contributory factor. We did not evaluate germline genomics, such as genes involved in immune mechanisms, inflammation, drug metabolism; therefore, we cannot rule out racial differences in germline genomics that could potentially affect the tumor microenvironment or response to treatment. Lastly, the cancer registry nature of the TCGA database is not conducive to study mechanisms underlying the associations between molecular factors and clinical outcome.
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